TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04800315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: Specified dosages on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: Specified dosages on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: Specified dosages on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dosages on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dosages on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dosages on specified days
Study: NCT05422976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVI-01
Description: High molecular weight Hyaluronic Acid
Study: NCT05492435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
Study: NCT04480086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivebresib
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivebresib
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivebresib
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivebresib
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivebresib
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral
Study: NCT06065150

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard support
Description: See arm/group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery proposed according to the radiological score
Description: * If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management.
Study: NCT05665842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Application
Description: The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
Study: NCT06526338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% IP-001 for injection
Description: Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection and Local Ablation
Description: Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection and Local Ablation
Description: Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Ablation Alone
Description: Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Ablation Alone
Description: Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
Study: NCT05293145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Building Futures Program Primary Services
Description: Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
Study: NCT05329103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Lyophilized powder reconstituted with D5W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Lyophilized powder reconstituted with D5W
Study: NCT05036707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenodiagnosis Ticks
Description: Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
Study: NCT06309394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
Study: NCT06239623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSI-1187
Description: Use ERK inhibitor JSI-1187 to treat solid tumor
Study: NCT05258669

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBV152
Description: Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BBV152
Description: Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
Study: NCT05340270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor+GP
Description: PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP
Description: Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
Study: NCT05965271

Intervention type: DEVICE
Intervention: Fabulous Thoracic Aortic Stent System
Description: Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
Study: NCT05665842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Training
Description: After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ.
Study: NCT05036707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: 2-3 mm skin punch biopsies will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood draw
Description: Peripheral blood draws will be performed.
Study: NCT05880043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-102
Description: GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-102
Description: GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
Study: NCT06533345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Psychology
Description: Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
Study: NCT05062395

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo FDG PET CT

Intervention type: OTHER
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET CT

Intervention type: OTHER
Intervention: Low Carbohydrate High Fat Diet
Description: low carbohydrate and high fat diet for 48-72 hours

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo FDG PET CT
Study: NCT06397521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crown lengthening
Description: Investigation of the three techniques for aesthetic crown lengthening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crown lengthening
Description: Investigation of the three techniques for aesthetic crown lengthening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crown lengthening
Description: Investigation of the three techniques for aesthetic crown lengthening
Study: NCT06533345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Treatments
Description: Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description.
Study: NCT05758155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental health literacy training supported by creative drama
Description: nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental health literacy training supported by classroom instruction
Description: nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
Study: NCT05555017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA-radioguided surgery
Description: Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I\&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
Study: NCT05627115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, AVD, Radiotherapy
Description: GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.
Study: NCT04553094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Aerobic circuit training
Study: NCT06479720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined pharmacotherapy with Solifenacin and Mirabegron
Description: Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
Study: NCT06649994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS of the DLPFC
Description: Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
Study: NCT06479720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin with vaginal estrogen cream
Description: Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron with vaginal estrogen cream
Description: Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Study: NCT05729594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Ophthalmic
Description: eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: eyedrops
Study: NCT05391165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back school
Description: Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
Study: NCT05132166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
Description: Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cells
Description: The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
Study: NCT06601192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelicapavir (therapeutic dose)
Description: Subjects will receive zelicapavir (TD) once per treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelicapavir (supratherapeutic dose)
Description: Subjects will receive zelicapavir (SD) once per treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive zelicapavir matching placebo once per treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: Subjects will receive moxifloxin once per treatment period.
Study: NCT06600906

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given intravenously (IV)

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given intravenously (IV)

Intervention type: PROCEDURE
Intervention: Computed tomography (CT)
Description: Undergo CT imaging

Intervention type: PROCEDURE
Intervention: Computed tomography (CT)
Description: Undergo CT imaging

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging
Study: NCT04553094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Aerobic circuit training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle building training
Description: Muscle strengthening circuit training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle building training
Description: Muscle strengthening circuit training
Study: NCT04375046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)
Description: In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV
Study: NCT04402242

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bispectral index
Description: Anesthesia monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index + NOL index
Description: Anesthesia monitoring
Study: NCT00000935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Description: given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immune globulin (IVIG)
Description: given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
Study: NCT05866224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Description: The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
Study: NCT04302324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Given as 1800mg via injection
Study: NCT05193721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1901
Description: SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
Study: NCT04786470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine infusion via transversus abdominis plane catheter.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline infusion via transversus abdominis plane catheter.
Study: NCT06476795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chardonnay Marc
Description: Food product made from Chardonnay wine grapes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chardonnay Marc
Description: Food product made from Chardonnay wine grapes